2024
A nomogram combining neutrophil to lymphocyte ratio (NLR) and prognostic nutritional index (PNI) to predict distant metastasis in gastric cancer
Liu J, Sun R, Cai K, Xu Y, Yuan W. A nomogram combining neutrophil to lymphocyte ratio (NLR) and prognostic nutritional index (PNI) to predict distant metastasis in gastric cancer. Scientific Reports 2024, 14: 15391. PMID: 38965325, PMCID: PMC11224267, DOI: 10.1038/s41598-024-65307-7.Peer-Reviewed Original ResearchConceptsNeutrophil-to-lymphocyte ratioPrognostic nutritional indexPlatelet-to-lymphocyte ratioSystemic immune-inflammatory indexLymphocyte to monocyte ratioMultivariate logistic regression analysisDistant metastasisLogistic regression analysisLymphocyte ratioReceiver Operating CharacteristicGastric cancerValidation cohortPredictive factorsRisk factors of distant metastasisDistant metastasis of gastric cancerNutritional indexImmune-inflammatory indexClinical practiceNomogram's predictive performanceDecision curve analysisGastric cancer patientsMetastasis of gastric cancerEfficient nomogramRegression analysisMonocyte ratio
2023
In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer
Lu L, Ma W, Johnson C, Khan S, Irwin M, Pusztai L. In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer. Vaccine 2023, 41: 2073-2083. PMID: 36813666, PMCID: PMC10064809, DOI: 10.1016/j.vaccine.2023.02.048.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, NeoplasmCA-125 AntigenCancer VaccinesEpitopes, T-LymphocyteFemaleHumansmRNA VaccinesOvarian NeoplasmsConceptsMRNA vaccinesOvarian cancerT cell responsesMutation-derived neoantigensT cell epitopesSARS-CoV-2Multiple neoantigensCytotoxic CD8Dendritic cellsCA 125Cancer vaccinesPatient survivalImmune responseCell epitopesNeoepitope peptidesNeoantigensVaccineCell responsesCancerBreastReverse vaccinologyCD8CD40LIFNNeoepitopes
2017
The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system
Yang C, Cheng H, Luo G, Lu Y, Guo M, Jin K, Wang Z, Yu X, Liu C. The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system. European Journal Of Surgical Oncology 2017, 43: 2112-2118. PMID: 28802662, DOI: 10.1016/j.ejso.2017.07.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCA-125 AntigenCarcinoma, Pancreatic DuctalCD4 Lymphocyte CountCD8-Positive T-LymphocytesFemaleFlow CytometryHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPancreatic NeoplasmsPredictive Value of TestsPrognosisRetrospective StudiesSurvival RateTumor BurdenConceptsCD4/CD8 ratioNew scoring systemAdvanced pancreatic cancerCD8 ratioPrognosis of patientsCA125 levelsPancreatic cancerScoring systemPrognostic valueHigher CD4/CD8 ratioMultivariate analysisAdvanced pancreatic cancer patientsComplete clinical dataHigher CA125 levelsKaplan-Meier methodIndependent prognostic factorPancreatic cancer patientsLog-rank testTumor immune responseCox hazard modelPrognostic factorsCancer patientsMetastasis statusClinical dataImmune response
2016
Which patients with para-aortic lymph node (LN16) metastasis will truly benefit from curative pancreaticoduodenectomy for pancreatic head cancer?
Liu C, Lu Y, Luo G, Cheng H, Guo M, Liu Z, Xu J, Long J, Liu L, Fu D, Ni Q, Li M, Yu X. Which patients with para-aortic lymph node (LN16) metastasis will truly benefit from curative pancreaticoduodenectomy for pancreatic head cancer? Oncotarget 2016, 7: 29177-29186. PMID: 27081079, PMCID: PMC5045387, DOI: 10.18632/oncotarget.8690.Peer-Reviewed Original ResearchConceptsPancreatic head cancerResectable pancreatic head cancerLymph node ratioHead cancerLymph nodesTumor locationPara-aortic lymph node dissectionPara-aortic lymph node metastasisPara-aortic lymph nodesCurative surgical resectionLymph node dissectionIndependent prognostic factorLymph node metastasisPoor surgical outcomesDuctal adenocarcinoma patientsPoor prognostic markerPreoperative serum CA125Curative pancreaticoduodenectomyNode dissectionPancreatic headRadical surgerySurgical resectionNode metastasisPrognostic factorsSuch patients
2015
Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer
Shi S, Ji S, Qin Y, Xu J, Zhang B, Xu W, Liu J, Long J, Liu C, Liu L, Ni Q, Yu X. Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. Cancer Letters 2015, 360: 227-233. PMID: 25687883, DOI: 10.1016/j.canlet.2015.02.014.Peer-Reviewed Original ResearchConceptsMetabolic tumor burdenMetabolic tumor volumeSerum tumor markersTumor burdenTumor markersPancreatic cancerAbnormal expressions of TP53Abnormal expressionMonitoring Treatment ResponsePancreatic cancer patientsProgression of pancreatic cancerExpression of TP53Tumor volumeCA19-9SMAD4/DPC4 geneTreatment responseCancer patientsDisease progressionPET/CTPredictive significanceSurvival rateLethal diseasePatientsCancerSerum
2014
Costs, Effectiveness, and Workload Impact of Management Strategies for Women With an Adnexal Mass
Havrilesky LJ, Dinan M, Sfakianos GP, Curtis LH, Barnett JC, Van Gorp T, Myers ER. Costs, Effectiveness, and Workload Impact of Management Strategies for Women With an Adnexal Mass. Journal Of The National Cancer Institute 2014, 107: dju322. PMID: 25515232, DOI: 10.1093/jnci/dju322.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlgorithmsBiomarkers, TumorCA-125 AntigenCost-Benefit AnalysisDecision MakingDisease ManagementFemaleGenital Neoplasms, FemaleHumansMaleMarkov ChainsMedicareMembrane ProteinsMiddle AgedPostmenopausePractice Guidelines as TopicPremenopauseReferral and ConsultationRisk AssessmentSEER ProgramSensitivity and SpecificityUnited StatesWorkloadConceptsPostmenopausal womenAdnexal massesCutoff valueEnd Results-MedicareState Inpatient DatabasesGynecologists guidelinesBiomarker validation studiesPremenopausal womenClinical outcomesGynecologic oncologistsInpatient DatabaseMalignancy AlgorithmSurgical volumeReferral strategiesTriage strategiesMedical costsRelative survivalPhysician workloadCA125Test characteristicsCost-effective strategyWomenTest sensitivityAmerican CongressMedicare reimbursement
2011
Serum Human Epididymis Protein 4 and Risk for Ovarian Malignancy Algorithm as New Diagnostic and Prognostic Tools for Epithelial Ovarian Cancer Management
Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, Tognon G, Bignotti E, Tassi RA, Odicino F, Caimi L, Sartori E, Santin AD, Pecorelli S, Ravaggi A. Serum Human Epididymis Protein 4 and Risk for Ovarian Malignancy Algorithm as New Diagnostic and Prognostic Tools for Epithelial Ovarian Cancer Management. Cancer Epidemiology Biomarkers & Prevention 2011, 20: 2496-2506. PMID: 22028406, PMCID: PMC3237732, DOI: 10.1158/1055-9965.epi-11-0635.Peer-Reviewed Original ResearchConceptsHuman epididymis protein 4Epithelial ovarian cancerSerum human epididymis protein 4Independent prognostic factorOvarian Malignancy AlgorithmPrognostic factorsMalignancy AlgorithmProgression-free survivalLymph node involvementOvarian cancer managementPreoperative serum samplesProtein 4Ovarian benign cystsElevated CA125Node involvementPositive cytologyPostmenopausal womenPremenopausal womenMultivariable analysisMulticenter studyPrognostic valueAdvanced ageOvarian cancerBenign cystsObstetricians stageLarge Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status
Skates S, Mai P, Horick N, Piedmonte M, Drescher C, Isaacs C, Armstrong D, Buys S, Rodriguez G, Horowitz I, Berchuck A, Daly M, Domchek S, Cohn D, Van Le L, Schorge J, Newland W, Davidson S, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff N, Fabian C, Sluss P, Nayfield S, Kasten C, Finkelstein D, Greene M, Lu K. Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status. Cancer Prevention Research 2011, 4: 1401-1408. PMID: 21893500, PMCID: PMC3172691, DOI: 10.1158/1940-6207.capr-10-0402.Peer-Reviewed Original ResearchConceptsHigh-risk womenCut-pointsMenopausal statusScreening TrialOvarian Cancer Screening TrialOvarian cancer screening studiesPopulation of high-risk womenOvarian cancer screeningPremenopausal womenStandard cut-pointCancer Screening TrialCancer screening studyEffect of menopausal statusPostmenopausal subjectsClinical factorsScreening studiesOral contraceptivesCancer screeningEarly detection of ovarian cancerCA125 testDetection of ovarian cancerGynecologic Oncology GroupEligibility criteriaScreening protocolDemographic dataPerformance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous Carcinoma
Gupta D, Gunter MJ, Yang K, Lee S, Zuckerwise L, Chen LM, Goldberg GL, Huang GS. Performance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous Carcinoma. International Journal Of Gynecological Cancer 2011, 21: 529-534. PMID: 21436701, DOI: 10.1097/igc.0b013e31821091b5.Peer-Reviewed Original ResearchConceptsUterine papillary serous carcinomaPapillary serous carcinomaCA125 levelsLymph node metastasisDisease recurrenceCA125 elevationMetastatic diseaseNode metastasisSerum CA125Serous carcinomaStage III/IV diseaseCox proportional hazards regression modelingProportional hazards regression modelingElevated CA125 levelsPreoperative CA125 levelsLymph node involvementRecurrence-free survivalAdvanced International FederationMultivariate survival analysisUPSC patientsMean followSurgical stagingCA125 measurementNode involvementIndependent predictors
2009
Peritoneal tuberculosis with elevated serum Ca-125 level mimicking advanced stage ovarian cancer: a case report
Tan O, Luchansky E, Rosenman S, Pua T, Azodi M. Peritoneal tuberculosis with elevated serum Ca-125 level mimicking advanced stage ovarian cancer: a case report. Archives Of Gynecology And Obstetrics 2009, 280: 333-335. PMID: 19184073, DOI: 10.1007/s00404-009-0946-y.Peer-Reviewed Original ResearchMeSH KeywordsAdultCA-125 AntigenDiagnosis, DifferentialFemaleHumansOvarian NeoplasmsPeritonitis, TuberculousConceptsSerum CA-125 levelsCA-125 levelsPeritoneal tuberculosisCA 125Elevated serum CA 125 levelsAdvanced stage ovarian cancerElevated serum CA 125Unnecessary extensive surgerySerum CA 125Resolution of symptomsFrozen section evaluationStage ovarian cancerAcid-fast stainOmental cakingAbdominal distentionExtrapulmonary diseaseNight sweatsDiagnostic laparoscopyCommon presentationExtensive surgeryMultiple granulomasPhysical examinationRadiologic studiesCase reportOvarian cancer
2008
Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer
Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. American Journal Of Obstetrics And Gynecology 2008, 200: 75.e1-75.e10. PMID: 18976739, DOI: 10.1016/j.ajog.2008.08.014.Peer-Reviewed Original ResearchConceptsPeptide-specific cytotoxic T lymphocytesCytotoxic T lymphocytesHuman leukocyte antigenLeukocyte antigenOvarian cancerT lymphocytesHuman cytotoxic T-lymphocyte responsesCytotoxic T-lymphocyte precursor frequenciesNatural killer-sensitive targetsPeptide-loaded target cellsType 1 cytokine profileCytotoxic T lymphocyte responsesT lymphocyte precursor frequenciesPotential immunogenic peptidesAdvanced ovarian cancerClass I antibodiesIntracellular cytokine expressionT lymphocyte responsesPositive healthy donorsInterferon-gamma productionT lymphocyte populationsPeripheral blood leukocytesCytokine profileELISPOT assayCytokine expressionTrefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas
Bignotti E, Ravaggi A, Tassi RA, Calza S, Rossi E, Falchetti M, Romani C, Bandiera E, Odicino FE, Pecorelli S, Santin AD. Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. British Journal Of Cancer 2008, 99: 768-773. PMID: 18682706, PMCID: PMC2528153, DOI: 10.1038/sj.bjc.6604546.Peer-Reviewed Original ResearchConceptsTrefoil factor 3Novel serum markerG3 EECSerum markersEndometrial carcinomaHigh-grade endometrial carcinomasEndometrial hyperplasia patientsEndometrioid endometrial carcinomaEndometrial hyperplasiaSerum levelsHyperplasia patientsHealthy patientsSerum concentrationsQuantitative real-time PCRHealthy controlsReal-time PCREndometrium biopsyTFF3 expressionPatientsTFF3 proteinEarly detectionGene expression profilingProtein levelsQRT-PCRExpression levelsTrastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu
Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. International Journal Of Gynecology & Obstetrics 2008, 102: 128-131. PMID: 18555254, DOI: 10.1016/j.ijgo.2008.04.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCA-125 AntigenDisease ProgressionEndometrial NeoplasmsFemaleGene Expression Regulation, NeoplasticGenes, erbB-2HumansImmunohistochemistryIn Situ Hybridization, FluorescenceNeoplasm Recurrence, LocalReceptor, ErbB-2TrastuzumabConceptsMetastatic endometrial carcinomaHER2/neuEndometrial carcinomaSingle agentCA-125 evaluationHER2/neu receptorRecurrent metastatic diseaseRecurrent endometrial carcinomaEffect of trastuzumabSerial CT scansViable therapeutic optionC-erbB2 gene amplificationSalvage chemotherapyClinical responseMetastatic diseaseTrastuzumab treatmentTherapeutic optionsStudy criteriaDisease progressionCT scanPatientsTrastuzumabNeu receptorChemotherapyRadiation treatment
2007
Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma
Huang GS, Chiu LG, Gebb JS, Gunter MJ, Sukumvanich P, Goldberg GL, Einstein MH. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecologic Oncology 2007, 107: 513-517. PMID: 17935762, PMCID: PMC2696225, DOI: 10.1016/j.ygyno.2007.08.060.Peer-Reviewed Original ResearchConceptsDeep myometrial invasionCA125 elevationExtrauterine diseasePrognostic factorsUterine carcinosarcomaPreoperative CA125CA125 levelsCA125 measurementMyometrial invasionPoor survivalExact testCox proportional hazards modelClinicopathologic prognostic factorsEstrogen receptor positivityIndependent prognostic factorManagement of patientsUnivariate survival analysisUseful serum markerPearson's chi-square testProportional hazards modelFisher's exact testChi-square testSerous histologyConsecutive patientsReceptor positivity
2001
The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences
O’Brien T, Beard J, Underwood L, Dennis R, Santin A, York L. The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences. Tumor Biology 2001, 22: 348-366. PMID: 11786729, DOI: 10.1159/000050638.Peer-Reviewed Original ResearchConceptsThreonine-rich sequenceAmino acid repeat unitsShort cytoplasmic tailAmino-terminal domainRepeat unitsTransmembrane domainCytoplasmic tailRepeat domainTerminal domainO-glycosylationBiological functionsRepeat sequencesCytoplasmic phosphorylationEpitope binding sitesExtracellular domainExtracellular structuresCysteine loopProtein coreTransmembrane glycoproteinLarge transmembrane glycoproteinProteolytic cleavageGenesBinding sitesPhysiologic roleSequence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply